Patent application number | Description | Published |
20100173312 | GENETIC LESION ASSOCIATED WITH CANCER - The invention comprises methods for identifying mutations within the 3′ UTRs of genes that lead to increased risk or probability of developing cancer. | 07-08-2010 |
20100190970 | GENETIC LESION ASSOCIATED WITH CANCER - The invention comprises methods for identifying mutations within the 3′ UTRs of genes that lead to increased risk or probability of developing cancer. | 07-29-2010 |
20120028254 | SNP Marker of Breast and Ovarian Cancer Risk - The invention provides methods for predicting an increased risk or probability of developing breast or ovarian cancer in a patient based upon the patient's KRAS-Variant and BRCA status. | 02-02-2012 |
20120115131 | GENETIC LESION ASSOCIATED WITH CANCER - The invention comprises methods for identifying mutations within the 3′ UTRs of genes that lead to increased risk or probability of developing cancer. | 05-10-2012 |
20120156676 | SINGLE NUCLEOTIDE POLYMORPHISMS IN BRCA1 AND CANCER RISK - The invention provides methods for identifying mutations, such as single nucleotide polymorphisms (SNPs), within breast and ovarian cancer associated genes that modify the binding efficacy of microRNAs (miRNAs). In a preferred embodiment, methods of the invention identify a SNP that decreases expression of the BRCA1 gene by increasing or decreasing the binding efficacy of at least one miRNA. Alteration of miRNA binding to BRCA1 by the introduction of SNPs within miRNA binding sites modulates or decreases BRCA1 expression, ultimately leading to the unregulated cell proliferation of a breast or ovarian cancer cells. | 06-21-2012 |
20120219958 | MicroRNA Signatures Differentiating Uterine and Ovarian Papillary Serous Tumors - The invention provides a papillary serous miRNA signature and methods for determining the identity, origin, and stage, of concurrent endometrial and ovarian papillary serous tumors. Exemplary origins of concurrent endometrial and ovarian tumors include, but are not limited to, the uterus, ovary, fallopian tubes, and peritoneum. | 08-30-2012 |
20130065778 | MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy - The invention provides miRNA signatures and methods of making and using thereof. MiRNA signatures determine the responsiveness of HER2 expressing breast tumors to anti-HER2 treatment, such as the targeted drug therapy trastuzumab. | 03-14-2013 |
20130089862 | Genetic Lesion Associated With Cancer - The invention comprises methods for identifying mutations within the 3′UTR of genes that lead to increased risk or probability of developing cancer. | 04-11-2013 |
20130252832 | KRAS Variant and Tumor Biology - The disclosure provides methods for identifying a subject at risk of developing cancer, predicting the onset of cancer, and predicting a subject's response to chemotherapy/treatment by determining the presence or absence of a SNP in the KRAS oncogene, known as the KRAS variant. | 09-26-2013 |
20140024590 | KRAS-Variant And Endometriosis - The invention provides methods for predicting an increased risk or probability of developing endometriosis in a patient based upon the patient's KRAS variant status. | 01-23-2014 |
20140065615 | The KRAS Variant and Tumor Biology - The disclosure provides methods for identifying a subject at risk of developing cancer, predicting the onset of cancer, and predicting a subject's response to chemotherapy/treatment by determining the presence or absence of a SNP in the KRAS oncogene, known as the KRAS variant. | 03-06-2014 |
20140206003 | Genetic Lesion Associated with Cancer - The invention comprises methods for identifying mutations within the 3′UTR of genes that lead to increased risk or probability of developing cancer. | 07-24-2014 |
20150025230 | Single Nucleotide Polymorphisms in BRCA1 and Cancer Risk - The invention provides methods for identifying mutations, such as single nucleotide polymorphisms (SNPs), within breast and ovarian cancer associated genes that modify the binding efficacy of microRNAs (miRNAs). In a preferred embodiment, methods of the invention identify a SNP that decreases expression of the BRCA1 gene by increasing or decreasing the binding efficacy of at least one miRNA. Alteration of miRNA binding to BRCA1 by the introduction of SNPs within miRNA binding sites modulates or decreases BRCA1 expression, ultimately leading to the unregulated cell proliferation of a breast or ovarian cancer cells. | 01-22-2015 |